TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In a randomized trial of 67 women with osteopenia or stable osteoporosis, those taking Pycnogenol, a French maritime pine bark extract, had better bodily-pain scores than placebo recipients after three months. The study was small, quality-of-life measures were secondary or exploratory outcomes, and its six-month design cannot establish long-term benefit or safety.
A randomized trial of 67 women with osteopenia or stable osteoporosis found that participants taking French maritime pine bark extract reported better bodily-pain scores than those taking placebo after three months. The finding, published in Frontiers in Nutrition, concerns a quality-of-life measure; it does not show that the supplement improves bone density or prevents fractures.
According to the trial report in Frontiers in Nutrition, the single-center, double-blind study assigned 33 participants to take Pycnogenol at 100 milligrams twice daily and 34 to take a matching placebo for the first three months. Participants then entered a three-month extension in which everyone received the extract. Seven participants withdrew during the six-month study: four from the original supplement group and three from the placebo group.
The researchers assessed quality of life using questionnaires, including the SF-36v2. On its bodily-pain scale, higher scores indicate less pain or better health status. The report says that at three months, the supplement group had significantly higher bodily-pain scores than the placebo group, including after adjustment for baseline scores. At six months, scores remained higher in the group that had taken the extract throughout than in the group that switched from placebo.
The trial report also describes higher vitality scores in the supplement group than the placebo group at three months, but says that difference was not maintained at six months. Other quality-of-life domains did not change over time. The authors state that the trial was powered for bone-turnover markers reported separately, while quality-of-life measures were secondary or exploratory outcomes.
Pain Scores, Not Bone Protection
Pain and reduced energy can affect daily life for people with low bone density, so a reported difference in bodily-pain scores may merit further study. However, as the trial report makes clear, the result is not evidence that the extract strengthens bones, reverses osteoporosis, or lowers fracture risk. The study assessed participants’ reported health status, not a demonstrated clinical benefit on those outcomes.
The finding also needs to be weighed against the study’s small sample and limited comparison period. Only the first three months included a placebo group. Once all participants received Pycnogenol, the six-month comparison could show how the original groups’ scores differed, but it could not measure the supplement against continued placebo. The trial report does not establish whether any change is meaningful to patients in everyday life or applies to a broader population.
Pycnogenol pine bark extract supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Trial Was Structured
The study report says participants were enrolled between October 2021 and January 2024. Eligibility was based on German guidelines and bone-density and fracture-risk assessments. The researchers excluded people taking ongoing anti-osteoporosis medication, those with recent osteoporotic fractures, and those using other nutritional supplements, subject to stated exceptions. This means the results do not automatically apply to people receiving standard osteoporosis medicines.
In the report, the authors describe Pycnogenol as a standardized extract of French maritime pine bark containing polyphenols, including oligomeric procyanidins. They discuss earlier preclinical research on possible antioxidant and anti-inflammatory effects, while noting that such findings do not establish a clinical effect on bone health in people. The authors also say earlier clinical studies had not directly assessed this supplement’s effects on bone health and quality of life in people with osteopenia or osteoporosis.
As an affiliate, we earn on qualifying purchases.
Limits of the Pain Finding
The trial report does not establish whether the difference in pain scores would persist beyond six months, produce a noticeable improvement in daily functioning, or occur in a larger and more varied group of patients. Because all participants received the extract during the final three months, there was no placebo comparison at six months. The study also was not designed to establish effects on fractures or changes in bone density.
Safety findings were limited by the trial’s size and duration. The researchers reported two mild, possibly treatment-related events: dizziness in a participant assigned to Pycnogenol and vomiting in a placebo participant. Both led to discontinuation. The report says no moderate or serious adverse events or clinically relevant laboratory abnormalities were observed, but the study cannot settle questions about longer-term safety.
low bone density pain relief supplement
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Evidence Needed
The study authors reported that bone-turnover marker results were presented separately; those findings should be considered on their own and do not change what this quality-of-life analysis establishes. Larger trials with longer follow-up and a placebo comparison throughout would help test whether the pain-score difference is reproducible, meaningful to patients, and sustained. Research would also need to examine bone-density and fracture outcomes directly before conclusions about bone protection could be drawn.
For now, the reported result is a preliminary quality-of-life finding, not a recommendation to replace prescribed osteoporosis care. People considering a supplement alongside treatment can discuss it with a qualified health professional, particularly because this trial excluded most participants taking ongoing anti-osteoporosis medication.
natural supplements for osteopenia
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the trial find?
According to the trial report, women assigned to Pycnogenol for three months had significantly better bodily-pain scores than women assigned to placebo. The study did not show that the extract improved bone density or prevented fractures.
How many people took part?
The study report says the trial enrolled 67 women: 33 were initially assigned to the extract and 34 to placebo. Seven withdrew during the six-month study.
Was the pain difference seen at six months?
The trial report says the group that took the extract throughout had higher bodily-pain scores at six months than the group that started on placebo. But both groups received the extract during the final three months, so this was not a placebo-controlled comparison at that point.
Did the researchers report side effects?
The researchers reported one case of dizziness in the Pycnogenol group and one case of vomiting in the placebo group. Both were described as mild and possibly treatment-related, and both led to discontinuation. The report noted no moderate or serious adverse events or clinically relevant laboratory abnormalities during the trial.
Does this mean the supplement treats osteoporosis?
No. The study examined quality-of-life measures, including pain, and does not establish that Pycnogenol treats osteoporosis, increases bone density, or reduces fracture risk. Its results also do not establish long-term safety.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
